News & Media

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright...

Press release 2021/08/31

Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the company has received regulatory approval from the British Medicines...

Press release 2021/08/19

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2021

April – June Financial summary for the quarter Net turnover amounted to SEK 0.9 (4.0) million. The loss before interest, tax,...

Press release 2021/08/16

Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB (“Medivir” or “the Company”) together with the originators...

Press release 2021/08/12

Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today that positive data from the investigator-initiated study evaluating the effects of remetinostat...

Press release 2021/08/05

Data from Medivir’s MIV-818 phase 1b study to be presented at the ESMO Congress

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that an e-poster entitled “Phase 1 study of the novel prodrug...

Press release 2021/07/01

Medivir appoints Malene Jensen as VP Clinical Development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She...

Press release 2021/06/01

Medivir to present at the Redeye Growth Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting Redeye Growth...

Press release 2021/05/25

Medivir to present at the ABGSC Life Science Summit

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will present at the virtual meeting ABGSC Life Science...

Press release 2021/05/25

Medivir announces the design of its upcoming MIV-818 combination study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced the details of its upcoming phase 1/2a combination study with the...

Press release 2021/05/20

Positive results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that results from the investigator-initiated phase II clinical study in patients...

Press release 2021/05/05

Resolutions at the Annual General Meeting in Medivir on 5 May 2021

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director...